Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : dsco Discovery Laboratories -- Ignore unavailable to you. Want to Upgrade?

To: gumbydamnit who wrote (13)	4/22/1999 5:03:00 PM
From: wontgetfooledagin	Respond to of 318

Interesting post regarding jnj, abt relative to dsco and the details of the price protection of the financing on Yahoo message board by otter. JNJ not only owns 1.2+m in dsco but they have a royalty agreement of 10%. He also said the price protection puts enormous pressure on mgt to get a deal done with in 5 months. For the price protection to have any detrimental effect to current shareholder 2 things have to happen. 1st the price of dsco has to average below $1.86 over a 5 week period prior to the end of the 5 month period. 2nd, management has to fail in securing a deal for over $10 million with a major pharma.

To: gumbydamnit who wrote (13)	5/4/1999 10:27:00 PM
From: FFNEODOC	Read Replies (1) \| Respond to of 318

See Recent Abstract regarding surfactant lavage for MAS treatment from the AAP's Journal Pediatrics, May '99 pediatrics.org "Barbara C. C. Lam and C. Y. Yeung From the Department of Paediatrics, University of Hong Kong, Hong Kong, China. Objective. Meconium aspiration syndrome (MAS) is a major cause of respiratory morbidity and mortality in term infants. We reported our pilot experience on the use of diluted bovine lung surfactant lipid extract solution (Survanta [Ross Laboratories, Ohio, USA]) as a tracheobronchial lavage fluid for the treatment of infants with severe MAS. Our goal was to establish the safety and the effectiveness of this procedure before organizing a randomized controlled trial. Method. Six infants with severe MAS necessitating mechanical ventilation with an oxygen index of 15 within 6 hours of life recruited consecutively during a 11/2-year period were treated with tracheobronchial lavage with 15 mL/kg of diluted surfactant solution (Survanta) at a phospholipid concentration of 5 mg/mL administered in 2-mL aliquots. The outcome of treatment was assessed by comparison with 6 consecutive historic control infants with equally severe MAS of similar inclusion criteria retrospectively. Results. The mean oxygen index, mean airway pressure, fraction of inspired oxygen, and arterial/alveolar oxygen tension ratio improved significantly within the first 48 hours after treatment in the lavage group. The duration of ventilation (mean ± SEM, 55.3 ± 4.6 hours vs 131 ± 60 hours) and oxygen therapy (mean ± SEM, 4.1 ± 0.5 days vs 20.8 ± 8.2 days) were also significantly reduced in the lavage-treated group compared with the control group. All 6 patients in the lavage group survived without sequelae whereas there were 2 deaths in the control group. The process of administering the surfactant lavage was well tolerated with no air leak complications. Conclusions. Our experience suggested that surfactant lavage seems to be an effective and safe method for treatment of severe MAS. A multicenter randomized control trial is indicated to further study the efficacy of this treatment. Key words: meconium aspiration syndrome, pulmonary surfactant lavage. "